The failure of clinical trials for a promising drug to slow dementia caused by Alzheimer’s is being seen as a disappointing setback, but not the end of hopes to fight the disease. On Wednesday, US drugmaker Eli Lilly announced that Phase 3 clinical trials of its drug solanezumab didn’t progress as planned. “Patients treated with […]
